Received Mar 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 4 | G36665 | — |
ITP; VIITP; This is a spontaneous report received from a Consumer or other non HCP, Program ID. A patient (age and gender not provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 03Jan2023 as dose 4 (booster), single (Lot number: G36665) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE, Unknown manufacturer), for Covid-19 Immunization; Covid-19 vaccine (DOSE 2, SINGLE, Unknown manufacturer), for Covid-19 Immunization; Covid-19 vaccine (DOSE 3 (BOOSTER), SINGLE, Unknown manufacturer), for Covid-19 Immunization. The following information was reported: IMMUNE THROMBOCYTOPENIA (hospitalization, medically significant), outcome "unknown", described as "ITP"; THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME (medically significant), outcome "unknown", described as "VIITP". Clinical course was reported as follows: On 03Jan2023, I received my 4th dose of Pfizer COVID vaccine (2nd booster) Lot # G36665. A few days later, I was admitted to the hospital, and was diagnosed with ITP. Tested for numerous malfunctions of my system, given several platelet transfusions and after 3 days in the hospital, I was released back to my home. I was ultimately diagnosed with VIITP.
Test Name: Investigation NOS; Result Unstructured Data: Test Result:Unknown results; Comments: tested for numerous malfunctions of my system